GlassScriptPhysician profile
Isaac J Klostermann
NPI 1386996080
$1,929.20
in general payments reported to CMS, 2019-2025
27 companies · $380 in 2025
The $380 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $414 · 2022: $287 · 2023: $374 · 2024: $475 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,228.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $562.50 | 2021-2025 | |
| Astellas Pharma US INC | $207.31 | 2021-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $165.31 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $134.85 | 2023-2025 | |
| Lilly USA, LLC | $104.40 | 2021-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $97.47 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $77.73 | 2022 | |
| Amgen INC. | $55.22 | 2022-2025 | Evenity |
| Medtronic, INC. | $47.20 | 2025 | Mycarelink |
| Otsuka America Pharmaceutical, INC. | $45.65 | 2025 | Rexulti |
| Teleflex LLC | $43.96 | 2021 | |
| Nestle Healthcare Nutrition INC. | $39.76 | 2021 | |
| Exact Sciences Corporation | $38.82 | 2023-2024 | Cologuard Collection Kit |
| Boston Scientific Corporation | $38.34 | 2025 | Axonics |
| Glaxosmithkline, LLC. | $34.88 | 2022-2025 | Trelegy Ellipta |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $31.89 | 2021 | |
| Edwards Lifesciences Corporation | $29.27 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Xeris Pharmaceuticals, INC. | $21.36 | 2021 | |
| Aimmune Therapeutics, INC. | $20.74 | 2024 | |
| Novo Nordisk INC | $19.61 | 2024 | Rybelsus, Ozempic |
| Biohaven Pharmaceuticals, INC. | $18.60 | 2021 | |
| Urogen Pharma, INC. | $18.09 | 2024 | |
| Merck Sharp & Dohme LLC | $17.91 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.20 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.56 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.78 | 2021 | |
| Myriad Genetic Laboratories, INC. | $12.79 | 2023 | Prolaris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isaac Klostermann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.